Key Takeaways & Executive Findings
- •• • DDY reduced pulmonary metastatic nodules to 2.4 per lung versus 21 in controls and 6.6 for free desloratadine in a 4T1 orthotopic breast tumor model (p < 0.01), demonstrating a >8-fold suppression of metastasis; this matters clinically because metastasis, not primary tumor size, drives mortality in triple-negative breast cancer. • • Immunohistochemical analysis showed drastic decreases in SLC7A11 and GPX4 levels in DDY-treated tumors, confirming ferroptosis as the mechanism of action; this provides a biomarker strategy for patient selection and suggests combination with ferroptosis inducers may overcome resistance. • • DDY exhibited selective toxicity against MCF-7, MDA-MB-231, and 4T1 tumor cells at concentrations up to 20.0 μM, while sparing normal MCF-10A breast cells; this selectivity index is critical for reducing off-target toxicity and enabling dose escalation in vivo. • • DDY administration significantly inhibited tumor growth to the smallest tumor volume and weight among groups and suppressed distal liver metastasis, with no significant effect on mouse body weight; this indicates a favorable therapeutic window and potential for chronic dosing in metastatic settings.
China Clean Energy & Battery Radar
Get verified English translations, SEM micrographs & open-access PDF alerts from China's leading state key laboratories delivered to your inbox every Monday at 08:00 EST.
Abstract
Intracellular drug partitioning dictated by chemical structure constrains therapeutic efficacy. Covalent organelle-targeting conjugates have enabled mitochondria (Mito) or endoplasmic reticulum (ER) delivery, yet simultaneous co-targeting with controlled parent-drug release remains unaddressed. We report a molecular delivery platform (DDY) that loads desloratadine (Des), an antihistamine with negligible anticancer activity, and responds to glutathione (GSH) to release Des selectively within Mito and ER of cancer cells. DDY exploits the elevated GSH in tumor cells to trigger ferroptosis while sparing normal breast cells. In 4T1 orthotopic breast tumor-bearing mice, DDY reduced pulmonary metastatic nodules to 2.4 versus 21 in controls and 6.6 for free Des, and suppressed distal liver metastasis. Immunohistochemistry revealed decreased SLC7A11 and GPX4, confirming ferroptosis involvement. DDY also inhibited tumor angiogenesis and induced Mito dysfunction. Body weights remained stable, indicating manageable metabolic toxicity. The platform converts an approved antihistamine into an effective chemotherapeutic via organelle-level redistribution, broadening the chemical space for drug repurposing.
1. Introduction
Covalent conjugation of organelle-targeting groups, such as triphenylphosphonium (TPP) for mitochondria, has enabled quantitative drug delivery to specific organelles. However, simultaneous co-targeting of multiple organelles with controlled release of the parent drug remains a challenge. Existing nanomedicines that co-target mitochondria and endoplasmic reticulum rely on two separate covalent conjugates, complicating synthesis and regulatory approval. The lack of a single molecular platform that can load a drug, target two organelles, and release the active agent in situ has stalled the translation of organelle-targeting chemotherapy.
This work introduces DDY, a molecular delivery platform that covalently loads desloratadine, an antihistamine with negligible anticancer activity, and responds to elevated glutathione (GSH) in cancer cells to release the parent drug within mitochondria and endoplasmic reticulum. By exploiting the redox disparity between tumor and normal cells, DDY selectively induces ferroptosis in cancer cells while minimizing toxicity to normal breast cells. The platform's efficacy in orthotopic and metastasis models demonstrates a viable strategy for repurposing approved drugs into precise chemotherapeutics, addressing the bottleneck of multi-organelle targeting with a single chemical entity.
Loading authentic research manuscript (Pages 1–5)...
WANG Ling-Li, ZHENG Ming-Hua, JIN Jing-Yi, ZHU Shoujun, ZHANG Songling (2025). Repurposing antihistamine to chemotherapy via a molecular delivery platform co-targeting mitochondria and endoplasmic reticulum. SCIENCE CHINA Materials. https://doi.org/10.1007/s40843-025-3447-4
Research & Educational Purpose Only: The translations, structured abstracts, analytical annotations, and data reports provided by SinoGreenTechare intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoGreenTech claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the mechanism of GSH-responsive release, and what is the effective GSH concentration threshold for selective activation in cancer cells?
DDY contains a disulfide linker that is cleaved by glutathione (GSH). Cancer cells exhibit GSH concentrations typically 2–10 mM, whereas normal cells maintain 0.5–2 mM. This differential allows selective release of desloratadine in tumor cells. The exact threshold was not quantified in the provided text, but the platform's selectivity was demonstrated in vitro across MCF-10A (normal) and MCF-7, MDA-MB-231, 4T1 (tumor) cells at concentrations up to 20.0 μM.
How does DDY's efficacy compare to standard chemotherapy in the 4T1 orthotopic model, and what are the quantitative metastasis outcomes?
In the 4T1 orthotopic breast tumor model, DDY reduced pulmonary metastatic nodules to an average of 2.4 per lung, compared to 21 in the control group and 6.6 in the free desloratadine group (p < 0.01). DDY also significantly inhibited primary tumor growth to the smallest tumor volume and weight among groups and suppressed distal liver metastasis. These results indicate superior anti-metastatic efficacy over the parent drug.
What are the key safety and toxicity profiles of DDY in vivo, particularly regarding body weight and metabolic toxicity?
DDY administration had little effect on mouse body weight over the treatment period, indicating minimal systemic toxicity. The abstract states 'manageable metabolic toxicity in vivo.' No mortality or severe adverse effects were reported. The selective toxicity against tumor cells versus normal breast cells in vitro further supports a favorable safety margin.
What is the scalability and cost of goods for synthesizing DDY, and are there any synthetic bottlenecks?
The provided text does not disclose synthetic yields or cost parameters. DDY is a small-molecule conjugate of desloratadine with a GSH-responsive linker and organelle-targeting moieties. Its synthesis likely involves standard organic reactions (amide/ester coupling, disulfide formation). Scalability would depend on the availability of desloratadine (generic, low-cost) and the targeting ligands. No data on batch size or purification challenges are given.
Does DDY induce ferroptosis exclusively, or are other cell death pathways involved? What evidence supports ferroptosis as the primary mechanism?
Immunohistochemical analysis of tumor tissues showed a drastic decrease in SLC7A11 and GPX4 levels, both key regulators of ferroptosis. This implies an essential role of ferroptosis in DDY administration. The text states that DDY 'effectively and selectively induces tumor cells to ferroptosis.' No other pathways were explicitly ruled out, but the biomarker changes strongly support ferroptosis as the dominant mechanism.
Related Chinese Research & Cross-Citations
Ammonium Vanadate Cathodes in Aqueous Zinc-Ion Batteries: Design Strategies and Research Progress
Aqueous zinc-ion batteries (AZIBs) offer a compelling combination of high safety, environmental compatibility, and abundant zinc resources, positioning them as viable candidates for grid-scale energy storage. Their practical deployment, however, is constrained by cathode materials that suffer from structural degradation, sluggish Zn2+ diffusion, and inadequate electronic conductivity. Ammonium vanadates (AVOs) have emerged as high-performance cathodes owing to their layered or tunneled frameworks, which accommodate reversible Zn2+ (de)intercalation with diffusion coefficients superior to conventional vanadium oxides. This review systematically examines recent advances in AVO cathodes for AZIBs, correlating morphological variations—including nanowires, nanobelts, and microflowers—with electrochemical characteristics. The analysis establishes structure–performance relationships that govern capacity retention, rate capability, and cycling stability. Key optimization strategies are critically assessed: defect engineering to enhance electronic conductivity and active site density, interlayer spacing modulation via pre-intercalated cations or structural water to facilitate Zn2+ transport, and composite construction with conductive carbonaceous or polymeric matrices to mitigate dissolution and improve mechanical integrity. Despite these advances, challenges persist in achieving long-term cycling stability (>10,000 cycles) and high areal mass loading (>10 mg cm-2) required for commercial viability. The review concludes by outlining future research directions, including operando characterization of degradation mechanisms and scalable synthesis routes for AVO cathodes in practical AZIB configurations.
Microenvironment-responsive therapeutic platforms: Innovations for spinal cord injury repair
Spinal cord injury (SCI) remains a formidable clinical challenge due to the complex, dynamic lesion microenvironment that impedes axonal regeneration and functional recovery. This highlight examines a microenvironment-responsive therapeutic platform integrating microneedle delivery, ferroptosis modulation, and hydrogen therapy. The platform leverages the pathological hallmarks of SCI—oxidative stress, iron dyshomeostasis, and lipid peroxidation—to achieve spatiotemporally controlled cargo release. By combining microneedle arrays for minimally invasive intraparenchymal administration with hydrogen-releasing biomaterials, the system addresses the dual bottlenecks of poor drug penetration across the blood-spinal cord barrier and insufficient neutralization of reactive oxygen species. Ferroptosis inhibition is achieved through iron chelation and glutathione peroxidase 4 (GPX4) stabilization, while hydrogen gas scavenges hydroxyl radicals and peroxynitrite. This multimodal strategy attenuates secondary injury cascades, reduces glial scar formation, and promotes neural stem cell differentiation. The work is supported by the National Natural Science Foundation of China (82574518) and the Talent Cultivation Project of Paring Academicians with Young Talents in higher education institutions in Zhejiang. The authors declare no conflict of interest. This highlight underscores the translational potential of microenvironment-responsive platforms for SCI repair, emphasizing the need for rigorous preclinical validation and scalable manufacturing.
Dual-Site Adsorption over Phosphorus-Doped Copper Oxide for Efficient CO2 Electroreduction to Ethylene
Electroreduction of CO2 to ethylene offers a promising route for renewable electricity storage, yet achieving high ethylene selectivity at industrial current densities remains challenging due to the large energy barrier for C–C coupling. Here, we report a “MOF-assisted in situ doping” strategy to introduce the oxophilic nonmetal phosphorus (P) into the copper oxide (CuO) lattice, constructing a localized Cu–P dual-site adsorption configuration for the key *OCCHO intermediate. The optimized catalyst delivers an impressive Faradaic efficiency of 64.6% for ethylene with a partial current density of 646 mA cm-2. Comprehensive structural characterizations demonstrate that P mainly occupies Cu sites, generating abundant lattice defects and oxygen vacancies. In situ synchrotron infrared spectroscopy and theoretical calculations reveal that P doping modulates the electronic structure of Cu, optimizes the binding energies of *CO and *CHO, and stabilizes *OCCHO via P–O/Cu–C dual-site adsorption, thereby significantly lowering the asymmetric C-C coupling energy barrier to 0.74 eV. This work highlights a dual-site microenvironment regulation strategy for CO2-to-ethylene electroreduction.
Hydrophilic Single-Atom Interface Unlocks Low-Potential CO Removal on Pt in PEMFCs
Proton exchange membrane fuel cells (PEMFCs) fed with reformate hydrogen suffer severe anode poisoning by trace CO, necessitating high CO electrooxidation potentials that degrade performance and durability. This work introduces a Pt@CrSA-N-C anode catalyst featuring a hydrophilic Cr single-atom interface that simultaneously weakens CO adsorption on Pt via electronic regulation and promotes water activation, thereby lowering the CO oxidation onset potential to approximately 0.13 V vs. RHE. The onset potential was determined by two independent methods: the first potential at which the background-corrected current exceeds 0 mA cm-2 during CO oxidation reaction tests in a three-electrode system, and the potential at which the forward scan current exceeds the N2 background current in CO-stripping voltammetry. The catalyst achieves a maximum power density under 100 ppm CO that surpasses reported advanced catalysts, as compiled in Table S5. Structural, spectroscopic, and electrochemical characterizations collectively establish a coherent rationale for the hydrophilic single-atom interface strategy. This approach addresses the longstanding trade-off between CO tolerance and Pt utilization, offering a viable route for low-potential CO removal in practical PEMFC anodes.
An Ionoelastomer-Based Bioinspired Wearable Electronics with Tele-Perception and Tactile Sensation for Machine Learning-Assisted Rehabilitation Management
Comprehensive assessment of rehabilitation efficiency is essential for designing appropriate training programs for better musculoskeletal functional recovery. Existing contact-receptor-dependent rehabilitation assessment systems mostly focus on assessing the restoration of muscle function by evaluating grip strength or joint flexion angle; however, parameters reflecting neuromuscular synergistic function are always overlooked. Herein, we develop an ionoelastomer-based soft artificial electroreceptor (SAER) that integrates tele-perception and tactile sensation to track the rehabilitation process, collecting signals related to approaching speed and grip strength sequentially. The SAER uses polyurethane ionoelastomer incorporated with quasi-solid conductive salt as the electric field receptor, and is integrated on a rehabilitation-training ball after assembly to establish an untethered detection device; this enables the remote capture of hand approaching parameter within a 9 cm range, followed by the quantification of grip strength when contacting and grasping. Furthermore, a data-driven assessment system is established by integrating machine learning, which accurately classifies rehabilitation efficiency into six levels; it supports for rehabilitation evaluation and training programs adjustment. Overall, the SAER-based rehabilitation management system establishes a paradigm that synergistically evaluating parameters corresponding to neuromuscular functional restoration and holds strong potential for home-based active rehabilitation for minimizing dependence on frequent clinical supervision.
Microwave-Absorbing Materials with Strong Environmental Adaptability for Corrosion Protection, Anti-Icing, and Thermal Management
Microwave-absorbing materials (MAMs) deployed on naval vessels, aerospace vehicles, and critical electronic systems face coupled electromagnetic, marine salt-spray corrosion, and extreme-temperature loads that legacy single-function absorbers cannot withstand. This review consolidates progress on three environmentally adaptive MAM classes: corrosion-protective, anti-icing, and thermal-management absorbers. The electromagnetic loss and impedance-matching fundamentals are first established, then the synergistic mechanisms, design strategies, and characterization protocols for each class are examined against representative material systems and their measured performance. The analysis identifies a shared design logic—multiscale hierarchical architecture, interfacial polarization engineering, and multifunctional phase integration—while distinguishing the divergent protection mechanisms: barrier and passivation effects for corrosion, surface-energy and latent-heat regulation for anti-icing, and phonon–electron transport decoupling for thermal management. Persistent bottlenecks include the trade-off between impedance matching and protective-layer density, the absence of standardized coupled-field test protocols, and the scarcity of long-term salt-spray and thermal-cycling durability data. Future directions are delineated: intelligent self-adaptive absorbers, multiphysics-coupled simulation frameworks, and environmentally benign multifunctional integration. The review provides a theoretical and technical basis for the design, construction, and engineering scale-up of next-generation high-performance absorbers for aerospace, electronic, and marine equipment.